30results about How to "Maintain affinity" patented technology

The present invention relates to the anti-human hepatocarcinoma McAb HAb18 heavy chain and light chain variable region genes, the polypeptides encoded by the same, as well as to their use in the preparation of a medicament for diagnosing and treating tumors or inflammation diseases. Based on the heavy chain and light chain variable region genes, various novel small molecule genetic engineering antibodies, including single chain antibodies, chimeric antibodies, Fab antibodies and the like can be constructed and expressed for the diagnosis and treatment of hepatoma.

Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.

The invention relates to a preparation method of a high-adsorptivity metal organic framework material and belongs to the technical field of adsorption materials. Two basic functional groups are simultaneously introduced into ionic liquid to synthesize the ionic liquid with double basic sites. The preparation method disclosed by the invention is characterized in that the modified prepared ionic liquid is loaded into a material pore to enable the material pore to keep a certain crystal form structure; along with the increase of the loading capacity, modified molecules occupy the pore channel, sothat the specific surface area, the pore volume and the pore size of a matrix framework material are reduced in different degrees; and by introducing groups, the affinity of a sample to CO2 is increased. Furthermore, the high-adsorptivity metal organic framework material prepared by the technical scheme of the invention can still keep certain regeneration stability after being cyclically regenerated for many times, and is a carbon dioxide adsorbent with good application prospects.

The invention discloses a method used for producing humanized antibodies or antigen combination fragments. The method comprises following steps: antibody heavy chain variable region and light chain variable region sequences of a non-human organism specific to a certain antigen are obtained; the sequences are compared with amino acid sequences of human embryonal system antibodies; human embryonal system amino acid sequences, which possesses highest homology with the heavy chain variable region and the light chain variable region of the non-human organism, are selectively respectively; human embryonal system antibody heavy chain and light chain variable region frame libraries are constructed, and a complete frame assembly library is assembled; the frame assembly library is expressed so as to obtain humanized heavy chain variable region and light chain variable region, which are capable of combining with the antigen, by screening, and realize preparation of the humanized antibodies or the antigen combination fragments of the humanized heavy chain variable region and light chain variable region. The method is capable of avoiding dependence on antibody structure analysis in antibody engineering processes, at the same, realizing screening on antibody expression and stability, and maintaining affinity of the humanized antibodies as far as possible.

An input / output (I / O) switch fabric includes first physical ports that convey multiple network flows. Moreover, classifiers in the I / O switch fabric separate packets for network flows associated with different types of service. Then, the I / O switch fabric conveys the packets to different virtual switch ports without interference between the separated packets associated with different network flows. Furthermore, second physical ports in the I / O switch fabric output the packets, where a given second physical port outputs packets for at least some of the network flows associated with different types of service. In this way, the given second physical port can output packets having: the same source and destination; different sources and the same destination; or the same source and different destinations.

The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and / or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematorsus.

The present invention relates to the anti-human hepatocarcinoma McAb HAb18 heavy chain and light chain variable region genes, the polypeptides encoded by the same, as well as to their use in the preparation of a medicament for diagnosing and treating tumors or inflammation diseases. Based on the heavy chain and light chain variable region genes, various novel small molecule genetic engineering antibodies, including single chain antibodies, chimeric antibodies, Fab antibodies and the like can be constructed and expressed for the diagnosis and treatment of hepatoma.

The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2′-position and the 4′-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.

The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and / or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematosus.

The invention discloses a method used for producing humanized antibodies or antigen combination fragments. The method comprises following steps: antibody heavy chain variable region and light chain variable region sequences of a non-human organism specific to a certain antigen are obtained; the sequences are compared with amino acid sequences of human embryonal system antibodies; human embryonal system amino acid sequences, which possesses highest homology with the heavy chain variable region and the light chain variable region of the non-human organism, are selectively respectively; human embryonal system antibody heavy chain and light chain variable region frame libraries are constructed, and a complete frame assembly library is assembled; the frame assembly library is expressed so as to obtain humanized heavy chain variable region and light chain variable region, which are capable of combining with the antigen, by screening, and realize preparation of the humanized antibodies or the antigen combination fragments of the humanized heavy chain variable region and light chain variable region. The method is capable of avoiding dependence on antibody structure analysis in antibody engineering processes, at the same, realizing screening on antibody expression and stability, and maintaining affinity of the humanized antibodies as far as possible.

The invention relates to a method for preparing photovoltaic silicon blade materials used for line cutting, comprises the following concrete steps of: 1. fine crushing: crushing silicon carbide raw materials; 2. chemical treatment: removing impurities by adopting deionized water and foaming agents; 3. standing treatment; 4. fine grading; 5. drying treatment; and 6 mixing and proportioning, wherein in the mixing and proportioning step, firstly, different batches are sorted after being detected according to particle shapes, rhombic granular materials and ball-shaped granular materials are mixed according to a mass ratio of 1 / 2, and packing is carried out after the sieving treatment. The invention has simple production process, can not cause any pollution on environment, in addition, the fine powder of the finely processed silicon carbide has high purity and concentrated granularity, the cutting efficiency can be improved, and the service life can be prolonged.

The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2′-position and the 4′-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.

The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more of the novel imaging agents of the invention.

The invention discloses a preparation method of oral nanoparticles for penetrating gastrointestinal mucus and epithelial cell barrier, comprising the following steps: (1) preparing a pH-responsive material: combining polyethylene glycol and stearic acid through an acylhydrazone bond Connect to obtain a pH-responsive material; (2) prepare a polymer material: connect the chitosan oligosaccharide and stearic acid through an amide bond to obtain a polymer material; (3) prepare a nanoparticle: combine the pH-responsive material of the above step (1). It is mixed with the polymer material of step (2), and a nano-coprecipitation self-assembly method is adopted to obtain a core / shell oral nanoparticle with the polymer material as the core and the pH-responsive material as the shell. In the nanoparticles obtained by the preparation method provided by the invention, the acylhydrazone bonds are broken and the polyethylene glycol shell is broken off in the mucus microenvironment, and the CSO-SA inner core is exposed, so as to realize the transition from hydrophilicity to hydrophobicity and near neutrality to positive charge on the surface of the nanoparticles Transition and increased adhesion, which in turn enhances its ability to cross the epithelial cell barrier, improve the oral absorption rate of the drug.

The invention discloses a humanized anti-IL-4R alpha single-domain antibody and application thereof, and relates to the technical field of antibodies. The anti-IL-4R alpha single-domain antibody disclosed by the invention has a complementary determining region and a humanized modified skeleton region. The anti-IL-4R alpha single-domain antibody provided by the invention is subjected to humanized transformation, so that the affinity and tumor cell proliferation blocking effect of the anti-IL-4R alpha single-domain antibody are maintained, and immune side reactions are effectively reduced.